Sagimet Biosciences (SGMT) Net Income towards Common Stockholders (2022 - 2026)

Sagimet Biosciences' Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$13.8 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 30.91% year-over-year to -$13.8 million in Q1 2026; TTM through Mar 2026 was -$69.9 million, a 46.13% increase from a year earlier, with the FY2025 full-year figure at -$54.8 million, up 51.02% from the prior year.
• Net Income towards Common Stockholders eased to -$13.8 million in Q1 2026 per SGMT's latest filing, from -$13.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$6.7 million in Q1 2023 and bottomed at -$82.6 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$15.1 million (2024), against an average of -$22.5 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 489.76% in 2023 and surged 83.82% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$11.2 million in 2022, then tumbled by 489.76% to -$66.0 million in 2023, then declined by 25.12% to -$82.6 million in 2024, then jumped by 83.82% to -$13.4 million in 2025, then fell by 3.37% to -$13.8 million in 2026.
• Per Business Quant, the three latest SGMT Net Income towards Common Stockholders figures stand at -$13.8 million (Q1 2026), -$13.4 million (Q4 2025), and -$20.0 million (Q3 2025).